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Abstract 
This paper explores the unique tensions and practical dynamics of pre-competitive 
consortia. As consortia can involve supply chain organizations, together with regulatory 
bodies and universities, participation is predicated by partners with markedly different 
outcome goals and risk dispositions. Some are willing to go ‘all-in’ for a long-term vision 
involving novel breakthroughs; others are focused on specific incremental gains. We draw 
from an eight-year dataset involving 98 entities, collaborating across five UK-based 
pharmaceutical sector consortia. We present case evidence from 14 projects where 
consortia are experimenting with a wide variety of digital initiatives, ranging from incremental 
to potentially game-changing (novel) innovations. A central issue here is the availability of 
alternative digital innovation pathways. So which pathway to take?  
We follow an abductive approach to examine the nature of these pathways and how 
consortia are organizing efforts for specific innovation performance and allied risk outcomes. 
We find that sequential pathways are characterized by ‘tactical gains’. Here, ‘attractive’ 
cases determine the pathway choice, resulting in follow-on incremental activities. In contrast, 
simultaneous pathways require hypotheses development where immediate ROIs are not 
always apparent. Here, the consortium effect ‘de-risks risk conversations’, enabling partners 
to get internal buy-in. Navigating such pathways within consortia has theory and practice 
implications. For example, a surprising finding is the going ‘all-in’ approach, often seen as 
loaded with risk, can be appropriate from a risk mitigation perspective for novel projects. As 
is the case with emerging consortia-led Covid-19 vaccines, where steps that are normally 
taken sequentially are being carried out simultaneously. 
 
Keywords: Consortia; Digitalization; Risk Mitigation; Project Management 
 
1. Introduction  
Advancements in digitalization across multiple technology disciplines has brought new 
requirements for network-centric innovation (Nambisan et al., 2017) as no single firm has the 
capability to fully exploit independently. This has led firms to enter pre-competitive 
collaborations involving consortia-based partnerships. University assessments of consortia-
SSRN Working Paper 
 2 
based partnerships have been widely described, however, industry perspectives are less 
well understood (Frølund and Riedel, 2018). In this in-depth study of pre-competitive 
consortia within the UK Pharmaceutical sector, spanning 2011-2018 and comprising 
research projects of value in excess of $100m, we have observed two types of innovation: 
those that involve multiple digital technology innovations within conventional research 
workflows, activities that broadly follow established design rules; and those that require new 
breakthrough approaches in support of more novel approaches. In this context, we observed 
pathways where network-centric digital innovations were managed either sequentially 
(‘spreading bets’) or simultaneously (going ‘all-in’). In this paper, we explore how operational 
risks are created and mitigated in each of these distinct pathways.  
Given the unique, evolutionary nature of our study, and as academic partners where we 
co-developed a succession of pre-competitive practitioner-inspired programmes, our 
scientific reasoning is grounded primarily in the post-factum theoretical interpretation of 
empirical observations. Through our case observations, we explore consortia efforts in 
realizing a series of digitalization initiatives with a view to offering plausible, conjecturable 
explanations (Bamberger, 2018) in the context of risk mitigation. With consortia partners now 
seeking to make sense of substantial follow-on investments, we look to inform future project 
selection and pathways to development. Given the unique tensions and practical dynamics 
at play, we outline how pre-competitive consortia might best organize for network-centric 
digital innovations, i.e., when to adopt a sequential pathway and when the simultaneous 
pathway is more appropriate.  
 
2. Bridging consortia and network-centric innovation research 
While there is significant prior work relating to innovation and networks (Powell et al., 1996), 
to our knowledge there has been no in-depth studies in the context of pre-competitive 
consortia engaging in digitalization R&D. Despite recent proliferation, few studies have 
assessed the operational effectiveness of consortia in reducing costs and risk (Papadaki and 
Hirsch, 2013). We pose a central question in whether alternative pathways in consortia-
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based innovation lead to alternative risk outcomes. Our eight year study offers first 
suggestions here. So how might consortia organize for digital innovations? They could 
‘spread bets’ and try to manage a wide portfolio of projects through multiple ‘coopetition’ 
arrangements (Gnyawali and Park, 2011; Pathak et al., 2014). However, these may require 
very different strategies, in refining existing and developing new knowledge with various 
levels of complexity (Chandrasekaran et al., 2016). So they might choose to manage 
projects either sequentially or simultaneously depending on novelty (Pich et al., 2002) or 
choose to ‘hedge bets’ and do both. But what proportion of resources should be directed to 
each type of pathway? From a practice perspective, a sequential or simultaneous pathway is 
often picked based on a business model, but what does this choice do to firms’ risk? In 
transitioning to digitalization, is the faster route riskier and the slower route less so? Yes 
seems the obvious answer. However, does this depend on whether the ultimate goal of a 
project is a conventional (conformance) or novel (performance) outcome? 
A central issue we tackle here is the availability of alternative digital innovation pathways 
within pre-competitive consortia. The literature is yet to address such pathways, where 
consortia activities span digital product-process and supply chain innovations. Given its 
focus on collaborative initiatives and shift from firm-centric to network-centric innovation, 
Nambisan and Sawhney’s study on orchestration processes (2011) appears a useful starting 
point in first understanding the nature of pre-competitive consortia. Second, by offering 
suggestions in constructing more accurate explanations of innovation processes and 
outcomes in digital contexts, Nambisan et al., (2017) provide a valuable taxonomy. They 
outline four new theorizing logics (one of which is orchestration) that are likely to be relevant 
in making sense of digital innovation pathways. In line with Dhanaraj and Parkhe (2006), we 
argue that orchestration and the network perspective is particularly relevant to our consortia 
context. However, while the three network mechanisms of leverage, appropriability, and 
coherence, have been assessing innovation from a strategic perspective (Nambisan and 
Sawhney, 2011), from an operational perspective open questions arise if alternative 
pathways will yield different types of outcome risk. We use these three mechanisms as our 
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conceptual foundation and examine how their interplay in pre-competitive consortia settings 
might shape outcome risks and vary across alternative digital innovation pathways.  
We define leverage as: how consortia are integrating unique member-specific 
knowledge, in terms of assets (innovation design) and relationships (network design); 
appropriability as: how consortia are realizing value in adopting new knowledge; coherence 
as: how consortia are coordinating and aligning member outputs and network outcomes in 
response to environmental conditions. Our unit of analysis is defined as a network-centric 
digital innovation, i.e., as a consortium-led project designed for specific outputs and 
outcomes, involving constructs and hypotheses, and with data collection and validation 
phases (Thomke, 2003). We classify network-centric outputs as those tangible standards, 
parameters and models that result from a consortium-led project (as opposed to a single 
focal firm supply network activity). For our practitioners, value creation without thinking about 
risk is not sufficient, as they are concerned with not just technological difficulty but also risk 
in regulatory and patient contexts. So we assess outputs in terms of both value creation and 
risk (conventional v. novel; high v. low); we classify network-centric outcomes as the benefits 
that a digital innovation is designed to deliver. In practitioner language, we assess in terms 
of network performance. We pose two central research questions: in leveraging and 
integrating consortia knowledge through appropriability, what are the risk implications of 
alternative pathways for conventional and novel outcomes (RQ1)? And what is the role of 
coherence in moderating and mediating the risk in these pathways (RQ2)?  
 
2.1. How are pre-competitive consortia organizing for network-centric innovation? 
The basis of this research is that no single firm can fully exploit digitalization R&D 
independently. This study is about pre-competitive collaborations involving consortia-based 
partnerships and not about a single focal firm network. The digital innovations we consider 
are relevant to several focal firms collaborating at the 'network'-level, yet may be competing 
at the 'firm’-level. We propose three alternative pathways that best capture network-centric 
digital innovations (see figure 1). Two pathways are sequential: (1) where digital product-
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process innovations (dPPIs) involve the digitalization of product-process first, and the supply 
chain may be digitalized subsequently; (2) where digital supply chain innovations (dSCIs) 
involve the digitalization of supply chains first, and product-process may be digitalized 
subsequently. Finally, a simultaneous pathway represents network-centric digital innovations 
involving both the digitalization of product-process and the supply chain in parallel.  
Practical examples of our dPPI projects include: (i) the digital design of molecules 
(product). With conventional lab-to-market timelines of 12 years, digitalization efforts around 
‘predictive capabilities’ focus on transitions from laborious physical experimentation and 
testing to rapid target molecule selection (end goal: to make synthesis of any desired 
molecule as easy as ‘dialling a number’). Outcomes here can facilitate increased success 
rates in identifying elusive molecules (see our case four on p.17), eliminating non-viable 
ones, with the potential to collapse development timelines by years and not months;  
 
Figure 1. Three alternative digital innovation pathways  
 
(ii) the digital design of routes to manufacture (process). For example, consortia efforts here 
focus on process analytics, ‘real-time’ information and ‘predictive’ control systems for the 
optimization of complex unit operations. Outcomes can enable the monitoring of critical 
process variables and their rapid extrapolation from lab to production settings via digital twin 
development (see our case 11, for an industry-first predictive model, on p.18). Some dSCI 
projects focus on write-offs of unused clinical stock, which is estimated to be $10-100 million 
for some consortia partners per annum. Practical examples involve new distributed 
manufacturing supply chain models, often enabled by dPPI outputs, that may offer step 
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technologies reducing lead-times from 4-6 months to <1 week (case 8), and process trials 
with potential savings of ~$3 million on materials and distribution per MNC per year (case 
15).  
 
2.2. Which type of study is appropriate for our context? 
While Nambisan and Sawhney (2011) may provide sufficient basis for formulating our two 
research questions, it is not possible to derive explicit a priori theoretical hypotheses. As our 
empirical context and data can ultimately lead to more general theoretical insights, this 
supports a theory-elaborating approach (Ketokivi and Choi, 2014). We use our base 
framework (Figure 1) to gather empirical and theoretical insights. To shed new light on 
potential mechanisms that might enable firms (through their consortia efforts) organize for 
network-centric digital innovations, we link our observations on pathways and dynamics to 
mid-range or intermediate theorizing (Edmondson and McManus, 2007). Here, an abductive 
mode of reasoning can offer first suggestions. Given the nature of our engagement as 
academic partners in practitioner-led consortia, this is in line with our remit to engage in 
research that tries to ultimately solve practical problems relating to the implementation of 
new digital innovations. Also, middle-range theorizing is an appropriate mode of enquiry in 
developing managerially relevant theories, especially because our application occurs in a 
specific context. With a limited range of data, this context (alternative digital innovation 
pathways in consortia setting) becomes of central importance. 
The empirical portion of this paper involves a multiple case study design (Yin 2003). The 
advantage of our design is confirmability and the potential to provide in-depth understanding 
and appreciation of context. A drawback is lower generalizability and transferability to other 
contexts. However, we take this ‘middle ground’ approach as our goal is intermediate 
insights in a specific consortia context. Our end-goal is not theory building or testing but to 
offer plausible post-factum explanations. Specifically, ways to make sense of our observed 
patterns in practice. Our case study approach relies on abductive inference in that we are 
elaborating on extant theories. Hence, our generalizations and explanations should be 
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interpreted as theoretical propositions. The main theory under elaboration is that of 
orchestration processes in network-centric innovation (Nambisan and Sawhney, 2011). 
 
3. Research Design  
In this section, we first outline the context behind our industry study. We then summarize our 
data collection activities between 2011 and 2018, in terms of case selection, consortia 
engagements, and network analysis. Further details on research phases, data sources, data 
collection instruments and analytical tools are provided in on-line appendix A1. 
 
3.1. Industry context and the rise of consortia 
The pharmaceutical sector has a long-standing reputation of being risk averse which has 
stifled innovation uptake compared to other related industries (Munos, 2009; Harrington et 
al., 2017). Two common issues that firms face are (i) the cost of poor quality relating to 
‘batch-to-batch’ variability in their processes and (ii) high levels of inventory. An inability to 
manufacture ‘right-first-time’ equates to global sector losses of $20 billion annually, with 
firms redirecting 15-20% of revenues to rework, inspection, and testing (Srai et al., 2015). 
The value of inventory, for the top 25 MNCs combined, is c. $100-150 billion (Daly et al., 
2015). These two issues have driven requirements for digitalization and subsequent 
industry-wide efforts in transforming outmoded practices and performance associated with 
the traditional ‘batch’ development-production-testing-‘make-to-stock’ regime (Leclerc and 
Smith, 2018). Early consortia efforts (c. 2011) involved predictive analytics and modelling in 
drug development (Dial-a-Molecule Grand Challenge Network) and the implementation of 
process analytics and ‘continuous’ technologies in drug production (CMAC Centre for 
Innovative Manufacturing). With some early ‘wins’, consortia members recognized they 
could capitalize on a wider variety of digitalization opportunities relevant to their respective 
segments through more pre-competitive collaborations. This culminated in the $30 million 
ReMediES Programme in 2014, with activities designed around supply chain innovation, 
increasing both network membership and scope. Combined CMAC and ReMediES efforts 
saw the launch of the Future CMAC Manufacturing Research Hub in 2017, which now 
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involves 10 of the largest MNCs (including AstraZeneca; Bayer; GSK; Pfizer) and specialist 
SMEs working on core technologies. By 2019, the CMAC research portfolio alone comprised 
of 80 projects, with 18 digital assets showcased. Figure 2 summarizes the make-up of three 
consortia in our study, some interconnected relationships, and the increasing scale of 
investment (i.e., $35 million UK government funding, matched by $65 million from industry). 
 
Figure 2. Snapshot example of consortia evolution in terms of members and investment 
 
3.2. Case Selection 
The first data collection activity involved case selection. With several consortia and literally 
hundreds of projects to choose from, we first looked to identify a reference population (Yin, 
1988). We included in the reference population only entities engaged in pre-competitive 
consortia that involved dPPI and dSCI activities and were collectively assessing new 
business models in different development–launch–supply scenarios. Given our unit of 
analysis and sector of interest, our reference population was also constrained to digital 
innovations involving drug development, production and/or supply. As such, we only 
considered dPPIs that demonstrated new functionality linked to digitally-enabled testing, 
validation or production (novel processing equipment and/or analytics), and dSCIs with the 
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We used a combination of industry study approaches (Joglekar et al., 2016; Srai et al., 
2016) to construct a current state view of the UK pharmaceutical sector, in order to identify 
information-rich cases. This served as the basis for capturing key actors, activities (i.e., 
evidenced dPPIs and dSCIs), consortia linkages, and our criterion sampling approach. From 
this, specific cases were identified from five pre-competitive collaborative UK-based 
consortia (see Appendix 1) where we evidenced firms accessing resources and capabilities 
across multiple partners to achieve necessary scale for digitalization R&D. In order to make 
inferences and maximise variation across our cases, stratified purposeful sampling (Patton, 
1990) was also employed based on specific applications (‘off-line’ v. ‘on-line’ testing; batch 
v. continuous processing; high/low volume and low/high variety contexts). We also looked to 
strategically arrange our sample into case pairs (where possible) to enable us to tease out 
more generalizable propositions and theoretical insights (Eisenhardt, 1989).  
In summary, 14 network-centric digital innovations were selected for analysis (two 
additional base cases served as our ‘points of departure’). Further details on our sample are 
outlined as part of our analysis in section 4 (see also Appendices 2-4) and a summary 
sampling grid (see on-line appendix A2). Cases 2-4 were representative of sequential 
pathway 1 and involved initiatives around molecule synthesis and crystallization unit 
operations. These two critical steps occur right at the start of the manufacturing process and 
determine the purity and particle size of most molecules. In turn, these two quality attributes 
directly impact other downstream processes and the therapeutic efficacy of overall drug 
performance. Hence, these specific unit operations are a strategic area of focus in the UK 
($55 million invested in the Future CMAC Manufacturing Hub). Cases 6-8 represented 
sequential pathway 2 and involved ‘intelligent’ pack technologies in both commercial and 
clinical contexts. In line with recent regulations around serialization (FDA, 2019), dSCIs 
focus on the ‘track and trace’ of drugs in commercial supply chains from point of 
manufacture to dispense. In a clinical supply context, we focused on how dSCIs might 
enable late postponement and product customization initiatives to eliminate costly inventory 
write-offs. This is a key sector goal as our consortium partners estimated that between 50–
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75% of clinical trial material is not dispensed, resulting in unnecessary waste. Finally, cases 
9-16 were representative of a simultaneous pathway. Using model (generic) molecules and 
existing standards as benchmarks, the eight network-centric digital innovations selected 
focused on achieving comparable performance (if not better and novel) involving selected 
batch and continuous processes and associated supply chain designs.  
 
3.3. Consortia engagements 
The second data collection activity involved our consortia engagements. We relied primarily 
on open-ended interviews with key consortia members and workshop-type engagements 
that focused on specific consortia goals. The overlapping nature of the five consortia 
(membership, geography, technologies, activities) enabled our exploration of specific and 
complementary dPPIs and dSCIs, which helped reduce both complexity and variation in 
terms of fit and context. Where applicable, we targeted engagement with universities, MNCs 
and SMEs involved in three or more of the consortia for data triangulation efficiency 
(Eisenhardt and Graebner, 2007). Our role as academic partner in three of the consortia 
also enabled ongoing access to expert informants over an eight-year period, and allowed for 
refinement and the gathering of additional data. Hence, we adopted a dynamic approach 
with respect to case analyses during three phases, and interview protocols in line with 
themes that emerged from interview and workshop activities (see on-line appendix A1). 
Specifics on workshop activities and respondents have been previously reported (reference 
removed). Once key themes emerged from initial rounds of interviews and workshops, we 
enriched the data with secondary data sources while triangulating information from senior 
industrialists. Our analysis also used basic coding techniques to try and gain further clarity 
on different contexts within our selected cases that were especially relevant in answering our 
research questions. We clustered interview and workshop data in order to open code 
‘conceptually similar events/actions/interactions’ (Corbin and Strauss, 1990, p.12) using the 
language of practitioners (e.g., did an output ultimately deliver ‘consistent’, ‘better’, or ‘novel’ 
outcomes?). We organized around our three network mechanisms as a basis of observation 
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(in terms of observed inputs and outputs), and subsequently looked for patterns involving 
themes and variables that emerged. In terms of validation, checks and balances were 
established and evidenced in contributions linked to targeted consortia outputs, e.g., MIT-
CMAC white paper series (Badman and Trout, 2015).  
 
3.4. Network Analysis 
The third data collection activity involved network analysis (NA) to draw further inferences for 
our sample. Given the complexities in effectively engaging with 98 entities across 5 
consortia, we worked with central nodes to gather data regarding structure and information 
flows between key partners (maximum number of nodes was fixed at 24). We used a NA 
approach where patterns and insights relating to specific communities could be identified 
(Parraguez et al., 2016). Consistent with their approach, we used the two-step cluster 
analysis algorithm (IBM Corp, 2001) as the basis for our analysis, because our data 
incorporated directed graphs. That is, these data mapped on to three networks that were 
representative of the three alternative pathways outlined in Figure 1. See on-line appendix 
A3 for graphical representations and further details on the three networks. 
A series of ‘sub-networks’ were identified from our NA and formed the basis of our 
observations in terms of inputs. Specifying precise inputs was an important task here as we 
wanted to link to specific consortia outputs. We categorised these observed inputs in terms 
of leverage, appropriability and coherence to operationalize, measure and compare cases. 
We deduced insights using metrics from NA and qualitatively through interviews with project 
leads and relevant experts, triangulating data with case anecdotes and review of relevant 
peer-reviewed publications. We defined leverage ratio as a measure of the direct 
connection of unique knowledge sources to the central nodes of the network under study. 
The basis of observation was the ‘Integration’ sub-network in each pathway. We defined the 
appropriability ratio as a measure of the uptake of new routines and standards emerging 
from network-centric digital innovations. The basis of our observation here was the ‘Design 
Rules’ sub-network. Finally, we defined coherence ratio as a measure of ‘transition to a 
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revised platform’ (Nambisan and Sawhney, 2011, p.46). Here, we looked at trade-offs and 
deduced whether digitalization might ease or constrain performance with the ‘Transition’ 
sub-network as our basis of observation. 
For subsequent observations of output, we used a fourth ‘Application’ sub-network. 
Applications were used to measure both the relative nature of value creation (conventional v. 
novel) and risk (low, medium and high) associated with the cases, by comparing them with 
the relevant base cases. We compared two base cases and any follow-on steps by revisiting 
a series of interconnected consortia funding proposals. We also reviewed relevant scientific 
articles linked to specific digital innovation outputs (e.g., Daly et al., 2015; Brown et al., 
2018). To dedude if the nature of value creation for specific applications continued to be 
conventional or were indeed novel, we explored how familiar respondents were with any 
novel performance parameters (i.e., had they observed and analysed a certain parameter at 
least once in a prior project). In terms of risk, we compared the same base cases with the 
sample and again deduced whether follow-on steps were deemed higher or lower risk, 
based on levels of variation observed for conventional and novel performance parameters.  
 
4. Empirical Observations  
In this section, we summarize our key empirical findings. First, we briefly outline our case 
sample and provide a summary of construct operationalization in terms of observed inputs in 
sections 4.1 and 4.2. We then summarize observed outputs and outcomes in section 4.3. 
and outline three empirical observations.  
 
4.1. Sequential Pathways  
4.1.1. Pathway 1 (dPPI First) 
This pathway was representative of coordinated academic-industry initiatives aimed at 
transforming 3-4σ sector performance to 5σ levels. In other words, reducing large batch-to-
batch variations (yields ranging anywhere from 93.3% - 99.4%) to achieve yields 
consistently >99.9%. Appendix 2 outlines a basic construct analysis for sequential dPPI 
cases 2-4. With molecule synthesis and crystallization unit operations considered as a dPPI 
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case pair, Batch development (case 1) served as our base case in terms of traditional 
laboratory bench-scale ‘make and test’ approaches. As basic trade-offs and single-firm 
optimizations around procedural norms and policies were common-place here, we 
categorized our constructs (leverage, appropriability, and coherence) as low.  
From this point of departure, we charted three dPPIs involving follow-on batch-dominant 
developments and their scale-up to material intensive commercial settings. Case 2 involved 
basic network initiatives that focused on reducing batch-to-batch variation in pilot and 
production settings. Here quality tended to be controlled through fixed process parameters 
and ‘off-line’ (destructive) end-product testing, with well-established rules on compliance to 
industry standards. So while there was some evidence of increasing leverage and 
engagement with selected partners, appropriability and coherence were categorized as low. 
Cases 3 and 4 involved dPPIs around batch processing that incorporated ‘on-line’ process 
analytics, and then a further transition from batch processing to hybrid (batch and 
continuous) modular systems, respectively. Here, more interdisciplinary networks were 
forming to collaborate on proof-of-concepts and research proposal development that 
focused on reducing batch-to-batch variation. With access to capabilities through increasing 
consortia engagements, leverage was categorized as high for the two cases. Case 3 
centered on consortia-driven development of Quality-by-Design (QbD) principles. Here, 
digitalization efforts (in the form of advanced control and monitoring strategies) had the 
potential to eliminate or reduce the need for physical testing. With QbD implementation by 
individual firms evidenced, informing more targeted designs for their specific batch 
operations, the uptake of more ‘on-line’ analytics also introduced different types of trade-offs. 
Consortia members described these as being of a cross-sectional nature (i.e., risk versus 
return) and appropriability and coherence were categorized as medium in this case. Finally, 
case 4 involved dPPIs around combined batch and continuous processing schemes, 
supported by model-based predictive control involving ‘real-time’ process measurement. 
With emerging quality assurance standards being evaluated by consortia members for their 
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own processes (appropriability seen as medium), leverage and coherence were categorized 
as high.  
4.1.2. Pathway 2 (dSCI First) 
This pathway was representative of specialized networks collaborating to improve non-
competitive aspects of demand and supply chains. Appendix 2 also outlines a basic construct 
analysis for sequential dSCI cases 6-8 . With a focus on mandated serialization and clinical 
supply wastage, Make-to-stock supply (case 5) served as a base case in this pathway. 
Traditional initiatives here have typically involved optimizing (reducing) the high levels of 
inventory associated with traditional batch processing models. We again categorized our 
constructs (leverage, appropriability, and coherence) as low for this base case.  
From this point of departure, we charted three dSCIs involving follow-on developments in 
material intensive clinical and commercial supply settings. Case 6 involved experiments in 
commercial supply using printed electronics for basic compliance and quality monitoring 
which shipments are generally subjected to, e.g., environmental parameters (temperature 
and humidity). While coherence was regarded as low, mandated serialization for effective 
‘track and trace’ of existing drug products has necessitated network formation around 
process and packaging redesign, and we categorized leverage and appropriability here as 
high. Case 7 was, in many ways, the polar opposite of our base case, with the development 
of lower volume dispersed ‘factory’ models. With consortia members looking to re-design 
supply chains for flexibility and agility in line with the development of more niche product 
variants targeted for sub-populations, we categorized leverage as high, and appropriability 
and coherence as medium. Finally, in this pathway, case 8 involved new trial designs to 
accelerate clinical and launch phases through ‘just-in-time’ operations. Regarding the 
current system, consortium members reported that it generally costs about $100 million to 
run a clinical trial for a new drug. This is a significant burden given that ~10% of drugs 
trialled only make it successfully through the development pipeline (DiMasi et al., 2016). As 
outlined in Appendix 2, we categorized leverage and coherence as high, and appropriability 
as medium. 
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4.2. Pathway 3 (Simultaneous)  
This pathway was representative of initiatives involving the development of dPPIs and dSCIs 
in parallel. Appendix 3 outlines a basic construct analysis for eight simultaneous cases, 
where base cases 1 and 5 both served as our starting point in this pathway.  
Case 9 was the first of two cases involving ‘end-to-end’ (E2E) proof-of-concept 
demonstrators (the other being case 16). Here, consortia were collaborating on concurrent 
workflow designs that integrated a series of dPPIs and dSCIs. We categorized all of our 
three constructs as medium in this case. Case 10 involved mobile technology platforms and 
the development of continuous process equipment that could handle a range of chemistries 
for selected processes. Here, we observed consortia bringing together technology 
companies and their end users to deliver solutions based around a scale-up platform for 
synthesis and separation unit operations. Here, we categorized leverage and coherence as 
high, and appropriability as low. As outlined in Appendix 3, this categorization also applied to 
cases 12 (cloud-based software systems and ‘smart label’ interventions for effective track-
and-trace) and 14 (new continuous processing technologies, including 3D-Printing, to 
increase the bioavailability of poorly soluble drugs). 
In terms of agile processes, case 11 involved the design of equipment and emerging 
predictive models for the continuous filtration of molecules (product). Continuous filtration, 
although well established in other process industries at large scale, has received less 
attention on smaller scales suitable for medicines manufacture. Here, we categorized 
leverage and coherence as high, and appropriability as medium in this case. This 
categorization also applied to cases 13 (miniaturized manufacturing platforms, with ‘real-
time’ process measurement and control for low volume and high variety contexts) and 15 
(next-gen materials for robust packaging to keep medicines dry, secure and free from 
contaminants). Finally, the Digitalization Lab (case 16) was a proof-of-concept reference 
facility set up to facilitate the integration of continuous manufacturing equipment streams 
and dSCIs (cases 9-15). Consortia members leveraged an open-access network of assets to 
quickly assess both firm-specific and consortia-specific projects (involving information 
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exchanges between upstream with downstream processes) and evaluate alternative 
business models. We categorized leverage and coherence as high, and appropriability as 
medium in this case. In terms of consortia inputs, one respondent commented on 
simultaneous pathway projects involving the ReMediES programme: 
“[it is] one of the early examples of the pharmaceutical industry working together in collaborative 
R&D, something it didn’t have a record of doing before…you don’t have to share your crown 
jewels … there are a lot of areas where companies can work together…which can benefit the 
whole industry….[it] will deliver some early wins…and longer-term impacts…Things happened 
that nobody would have believed possible at the start”.          (CMAC Advisory Board Chair) 
 
4.3. Observed outputs and outcomes 
In line with our abductive approach, we used our data to describe phenomena we observed, 
in order to tease out tentative claims and narrow a range of possible explanations (Folger 
and Stein, 2017). Figures 3-6 summarizes observed outputs in terms of value creation and 
risk. A summary of outcomes (network performance) are outlined in Appendix 4. Further 
details are provided in on-line appendix A4. Patterns indicative of alternative dynamics, 
processes, and/or mechanisms were identified by filtering the dataset and we used 
contrastive reasoning to provide three empirical observations.  
 
4.3.1. Increasing Leverage  
We explored leverage effects by observing how integration sub-networks were coordinating 
projects in sequential and simultaneous pathways. We examined how unique member-
specific knowledge emerged and the nature of its uptake by other consortia members. We 
summarize outputs (through filtering) in Figure 3 and provide brief examples to support 
observed patterns using selected cases. In summary, increasing leverage (over the base 
cases) was associated with five cases where outputs were classified as conventional and of 
low risk. Four such cases were sequential, and one case was simultaneous. In contrast, 
increasing leverage was associated with nine cases where outputs were seen as novel and 
of higher risk. Here, two cases were sequential, while seven cases were simultaneous.  
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For sequential case 2 (conventional value and low risk), outputs have continued to result 
in multiple — albeit small — changes to existing batch-based processing routines at 
molecule synthesis and crystallization. 
 
 
Figure 3. Increasing leverage cases – where outputs were deemed conventional or novel  
 
A key barrier to transformational change is that many batch-mode routines continue to 
require multiple time-consuming ‘work-up’ operations post each step. Historically considered 
in isolation, these have served to negate some of the benefits of multiple incremental 
improvements made at molecule synthesis and crystallization in terms of quality (reducing 
variability in particle size). Unintended consequences are common-place for downstream 
unit operations from synthesis and crystallization in ‘batch’ manufacturing (i.e., variability in 
particle size being especially problematic at filtration steps, with serious implications for 
yield).  
In contrast, for sequential case 4, ‘data-driven’ network-centric innovations have opened 
up the potential to transform the very nature of chemistry through better prediction of 
molecule-critical attributes and characteristics for rapid ‘scale-up’. Industry-first 
breakthroughs involving elusive forms of target molecules have been achieved. 
“…this has…rarely been achieved by design…in this work such a designed process is not 
only achieved, but scaled to produce large quantities of an elusive [molecule] with enhanced 
physical properties” (Agnew et al., 2016, p. 7368) 
 
Increased visibility on unique knowledge sources, involving such continuous-mode 
breakthroughs, has enabled consortia members to link outputs to promising network-centric 
innovations at other difficult downstream processes. For example, there were higher levels 
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of confidence evidenced in integrating sequential case 4 outputs and simultaneous case 11 
outputs. Here, consortia-led developments recently showcased the rapid determination of 
filtration parameters for new (and more challenging) molecules: 
[With an industry-first predictive model for filterability]…”scale-up to continuous operation then 
represents lower risk…which has very different characteristics to manual laboratory process 
development or to current batch operations” (Ottoboni et al., 2019, p.381). 
 
In conclusion, based on the patterns we observed, we can deduce the following: 
Empirical Observation 1: Increasing leverage (over the base cases) was associated with 
67% of sequential cases and 12% of simultaneous cases where outputs were deemed 
conventional and of lower risk; conversely, increasing leverage was associated with 33% of 
sequential cases and 88% of simultaneous cases where outputs were deemed novel and of 
higher risk. 
 
4.3.2. Increasing Appropriability  
We explored appropriability effects by observing ‘knowledge mixes’ in sequential and 
simultaneous pathways. That is, whether design rules sub-networks were reusing existing 
knowledge, or utilizing new consortia-derived knowledge, or a mix of both. We examined 
new routines and standards emerging from our cases and how consortia members also 
benefited from their contributions. We summarize outputs (through filtering) in Figure 4 and 
provide brief examples to support observed patterns using selected cases. In summary, 
increasing appropriability (over the base cases) was associated with four cases where 
outputs were seen as conventional and of low risk. Three cases here were sequential and 
one case was simultaneous. In contrast, increasing appropriability was associated with six 
cases where outputs were seen as novel and of higher risk. Here, two cases were 
sequential and four cases were simultaneous. 
In assessing emerging regulations around serialization and digital standards, the easier 
(lower risk) option has seen single-firm optimizations that just follow the same rules (e.g., for 
compliance). Such internal initiatives tend to self-serve and were often characterised by 
transitory exchanges with the regulator in seeking approval for incremental modifications to 
existing routines.  
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One area of focus has been the development of Quality-by-Design (QbD) principles by 
consortia where outcomes might result in less physical testing. While sequential dPPI 
progressions in digital production contexts have delivered some conventional value in terms 
of enabling data and information exchanges (case 3), implementing analytics linked to QbD 
principles for the ‘real-time’ release of products has long been an ambition (Yu et al., 2004) 
but not yet realized. 
 
Figure 4. Increasing appropriability cases – where outputs were deemed conventional or novel  
 
This is also being tackling in simultaneous pathways with case 9. Low risk feasibility demos 
– evaluating against existing standards – were commonplace in providing ‘first steps’ 
towards QbD through the predictive design of critical quality attributes (CQAs). An 
overarching workflow for the selection of overall process architecture, and setting of new 
standards, is a desired outcome here longer-term. However, follow-on experiments are 
required to address several limitations (e.g., the development of several workflows for unit 
operations downstream from molecule synthesis and crystallization and linking to E2E 
supply chain designs).  
In contrast, novel dPPI outputs in both sequential and simultaneous pathways were 
being actively accessed with a view to utilizing new consortia-derived knowledge. In 
commenting on applying consortia feasibility learnings to problematic firm-specific batch 
processes, one partner saw the definition and prediction of ‘ideal’ process states, linked to 
CONVENTIONAL NOVEL
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cases 4 and 13, as something they could readily exploit in their firm; the other partner saw 
the same output as being more explorative in nature: 
“the introduction of [novel] continuous seeding approaches developed with CMAC…into our 
scale-up operations allows for more consistent operation and predictable product 
properties”                              (Development Fellow, Novartis) 
 
“Overall it was a very valuable collaborative experience. I was really impressed that all the 
experiments in all equipment scenarios gave meaningful results…insights which have 
changed the way we think about our crystallization [unit operation]’.  
        (Technology Manager, Syngenta) 
 
Similarly, for dSCIs, sequential case 8 outputs have now made it possible to segment by 
product type (e.g., small molecule, formulation type, chemistry, stability), study design 
(complexity, shelf-life, phase and speed), customer demand profiles, technologies and risk 
profiles, in some cases. Emerging supply chain design rules and a more systems approach 
provided have improved conceptualisation and a modelling-based evaluation of supply chain 
configuration options. For consortia membership, this has enabled more ‘customized’ 
analysis in practice, with individual firms identifying what may be most critical for them in 
maximizing impact. Commenting on the benefits for his firm and for other consortia 
members, the project lead stated: 
“We prototyped a new ‘just-in-time’ clinical pharmacy that can…support complex drug trials, 
thereby reducing costs, increasing responsiveness and enabling a more flexible and exploratory 
approach to clinical research…modelling of stock implications [has demonstrated the] potential 
benefit of…savings of £10s of millions per year per company.” (GSK Project Lead, 
ReMediES Clinical Platform) 
 
In conclusion, based on the patterns we observed, we can deduce the following: 
Empirical Observation 2: Increasing appropriability (over the base cases) was associated 
with 50% of sequential cases and 12% of simultaneous cases where outputs were deemed 
conventional and of lower risk; conversely, increasing appropriability was associated with 
33% of sequential cases and 50% of simultaneous cases where outputs were deemed novel 
and of higher risk. 
 
4.3.3.  Relationship of Coherence to Leverage and Appropriability 
 
Using observed inputs from all cases (see again Appendices 2 and 3), we charted 
transitions to new digitalization arrangements in sequential and simultaneous pathways. We 
then examined the role of coherence and the nature of trade-offs using the transition sub-
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network as the basis of observation. This transition sub-network was seen as the the linking 
mechanism between the integration and design rules sub-networks so we looked for 
patterns in terms of the relationship of coherence to leverage and appropriability 
respectively. Limitations of space constrain a full presentation of our comparative analysis, 
so we provide a summary in Appendix 4 and represent leverage—coherence—
appropriability patterns graphically in Figure 5.  
We observed that the nature of coherence appears to be fundamentally different in 
sequential and simultaneous pathways. Recall from cases 1 and 2, that traditional control 
strategies have been based around fixed recipes and profiles. For the sequential dPPI 
pathway, subsequent outputs relating to the quality control of selected unit operations are 
now enabling ‘near-continuous’ monitoring in practice with the adoption of advanced control 
‘on-line’ strategies for specific processes. 
 
Figure 5. Relationships between leverage, coherence, and appropriability for the case sample 
 
Upstream and downstream operations (to molecule synthesis and crystallization) 
continue to be ‘batch’ or ‘semi-continuous’ and operated as decoupled operations often with 
independent coordination and governance mechanisms. In the other direction, sequential 
dSCI pathway outputs could be described as ‘edge-to-edge’ (they are doing this either ‘at 
the edge’, isolated from the main business or in ways which provide incremental 
improvements to their current activities) as opposed to ‘end-to-end’ in disrupting industry 
practices built around traditional ‘make-to-stock’ models. Here, for the most part, outputs 
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have enabled a reduction in investments at risk via delayed decision requirements (spanning 
both development-clinical and production-commercial contexts). 
In contrast, we observed the nature of know-how exchange to be fundamentally different 
in the simultaneous pathway. We observed a distinct shift from ‘standard’ dialogues and 
‘passive’ interactions towards ‘unique’ conversations beyond the ‘norm’. Predictive models 
were seen as essential building blocks for design rules that enabled transitions in 
simultaneous pathways. In meeting future market requirements to support lower-volume, 
high-variety niche products, simultaneous pathways also highlighted the need for new 
design rules around ‘scale’. For example, for integrating smaller footprints — in setting up 
‘end-to-end’ configurations that offered both flexibility in terms of production capacity, and 
speed in terms of ‘scale-up’ and ‘scale-out’. In translating novel consortia know-how to their 
technology platform, one consortium member commented:  
“This work…will be the basis for a core particle size control strategy in our continuous 
manufacturing platform…[it] offers superior particle size control in a shorter timeframe than 
traditional approaches. It is expected to save significantly on operator time and equipment 
use….The achievements were beyond expectations.”       (CMAC Industrial sponsor, Firm X) 
 
Desired outcomes appeared as polar opposites to those of traditional high volume-low 
variety blockbuster business models and challenged the traditional location-decision logic 
(and that of the ‘large batch’ pharmaceutical plant). With new systems comes the need for 
new regulations, where regulatory confidence and internal buy-in was of paramount 
importance to consortia members. This was the goal in developing the reference facility 
(case 16) with an entirely digitalized and virtual approach to the design and launch of new 
products. Here, the traditional practice where products are taken through design, 
manufacturing and supply stages sequentially and separately, was replaced by a digital 
approach that enabled dPPIs and dSCIs to be connected in a continuous E2E manner 
(cases 13-15). Rather than identifying and solving problems in isolation, manufacturing 
challenges were viewed holistically and managed as a consortium effort. According to one 
consortium project lead:  
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“we needed to make the required transition real to people — including having a working 
production unit — so they could experience physically what can be achieved, and also embrace 
the changes and challenges associated with it”  (Digitization lab lead, GSK) 
 
Finally here, we observed how multiple partners are now required to deliver a wide-
ranging set of applications. For example, future large-scale integration of ‘point-of-care’ 
solutions that might well require risk mitigations beyond some of the more traditional risk 
approaches identified for disruptive innovation. Reflecting on dPPIs and dSCIs, designed 
around what he described as two overriding workstreams or ‘platforms’, one stakeholder 
commented on the consortium infrastructure:  
‘Before… [the consortium launched] collaborations were on [a] scale of each of our 
individual workstreams. We were advised that a programme with 24 partners, and the breadth of 
work…would be unmanageable. We managed to achieve this super-sizing by finding 
coherent themes, creating technical workpackages or Apps [applications], that sat within our 
two overriding workstreams for the clinical and commercial supply chains.’    
        (ReMediES programme co-designer and steering group member) 
 
In conclusion, in examining the patterns between leverage, coherence, and 
appropriability for the case sample, we can deduce the following: Empirical Observation 3. 
Coherence and Leverage were aligned in 100% of the simultaneous cases and 33% of the 
sequential cases; Coherence and Appropriability work in the opposite direction, thus 
Coherence is associated with a variation in the moderation and mediation effect. 
 
5. Empirical Generalizations and Theoretical Interpretation 
Based on our summary of key empirical observations in section 4, we now look to give them 
plausible theoretical interpretations. This is common-place in theory-elaborating cases that 
rely on abductive reasoning, and in the post-factum interpretation of empirical data (Dubois 
and Gadde, 2002). First, we revisit our two research questions from section 2. What we can 
say with some confidence is: digitalization is forcing organizations to radically reconfigure, to 
decouple functional silo or single-firm optimizations, and adopt more ‘platform-based’ 
strategies involving both sequential and simultaneous pathways. The overarching 
interpretation of our observations is: digitalization is forcing firm sponsors and academic 
investigators who are structuring and managing consortia, and innovators operating within 
consortia-led projects, to engage in sensemaking and realignment. This is in line with 
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Holmström et al (2020, p.731) who report that ‘digitalization…[is placing] conventional 
OSCM systems under stress’. Specifically, digital innovators concern themselves with how 
and where return on investments (ROIs) and risk might drive pathway choices.  
Hence, we give first insights on how consortia and their members organize and behave 
(often very differently) in transitioning, and offer a plausible mechanism that might inform 
firms when thinking about and managing certain environmental conditions. Recall RQ1 from 
section 2 (i.e., what are the risk implications of alternative pathways for conventional and 
novel outcomes?). Here, we offer two empirical generalizations:   
Empirical Generalization 1: When value creation is conventional, sequential network-
centric digital innovations reduce risk when consortia members are able to highly leverage 
and integrate member-specific knowledge through appropriability; conversely, simultaneous 
network-centric digital innovations increase risk 
 
Empirical Generalization 2: When value creation is novel, simultaneous network-centric 
digital innovations reduce risk when consortia members are able to highly leverage and 
integrate member-specific knowledge through appropriability; conversely, sequential 
network-centric digital innovations increase risk 
 
In terms of RQ2 (i.e., what is the role of coherence in moderating and mediating the risk 
in these pathways?), we summarize our theoretical elaboration in variance theory form:  
Theoretical Elaboration 1: With sequential network-centric digital innovations, coherence 
both mediates and moderates the relationship between leverage and appropriability; with 
simultaneous network-centric digital innovations, coherence moderates the positive 
relationship between leverage and appropriability. 
 
Figure 6 elucidates the dynamics by which ‘knowledge mixes’ may be adjusted over time 
in sequential and simultaneous pathways. This integrated view of our two empirical 
generalisations and one theoretical elaboration involving digital innovation pathways is 
consistent with Martin and Eisenhardt’s stipulation on synthesis (2010) with its clear 
illustration of the underlying casual relations observed. In summary, sequential pathway 
mechanisms are both moderated and mediated by modular moves in transitioning 
(coherence). This is characterized by firms largely leveraging legacy systems with ‘one side’ 
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digitalized first to ensure a ‘rapid’ test to determine success or failure. Firm- and consortia-
level digital innovations can take many forms yet are based on conventional performance 
measures such as cost, quality, service, and dependability (and an ability to offer consistent 
or better improvements). With simultaneous pathways, network-centric digital innovations 
imply new technologies, standards, and radically different interpretations of performance 
measures. The risks in transition are being moderated by the presence of new network-
centric constructs (coherence). This pathway forces organizations to radically reconfigure 
and to rethink production/supply/regulatory networks and business models in tandem. For 
example, pre-competitive consortia have been ‘proactive’ in efforts to deliver novel systems 
and new regulations in a ‘non-conventional’ manner, as evidenced by ‘end-to-end’ digital 
demonstrators (linked to our cases) that do not always operate under current regulations. 
[This is also the case with emerging consortia working on Covid-19 vaccines. Here steps 
that are normally taken sequentially (and involve years) are being carried out simultaneously 
(in less than a year), e.g., managing large-scale clinical trials across 150 sites globally to 
qualify novel vaccine technologies, and scaling up manufacturing capabilities to produce 
billions of doses, and setting up the ultra cold-chain infrastructure to distribute vaccines, 
stored between -4 to -94 degrees Fahrenheit, around the world – all in parallel].   
   
Figure 6. Alternative consortia-led digital innovation pathways: an integrated mechanism 
 
As our research remit was about ‘discovery’ and conjecturable explanations, we 
recognize the difficulties in providing validated results or compelling evidence in places. This 
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and inductive reasoning (Bamberger, 2018). So, in order to establish plausibility, we discuss 
and look to support the theoretical interpretations of our observations in sections 5.1-5.3. 
 
5.1. Leverage - making the most of ‘consortia effects’  
Recalling our definition of leverage from section 2, what is common across all cases is that 
integration sub-network actors served as a ‘backbone’ in aligning network members and 
activities with the strategic goals of multiple consortia. In practical terms, individual firms 
were able to leverage resources, upwards of 50% in terms of direct activity, and by over 
300% at a consortium level (Badman and Srai, 2018). One plausible explanation is that 
optimal consortia network structures were shaped based on the objectives of its members 
(Ahuja, 2009) and that ‘network effects’ were in play, evidenced by our increasing leverage 
cases (recall figure 3) and growth of consortia membership (Iansiti and Levien, 2004). We 
also observed that the strength of these ‘network effects’ could vary dramatically in each 
pathway with consequences for value creation. This was consistent with Zhu and Iansiti 
(2019) who outlined that the strength of these effects could vary but also change over time. 
Indeed, in this 8-year study, a form of ‘relationship coordination’ served to reduce the 
amount of load on academic-industry networks as a whole, which enabled consortia to 
shepherd choices over time and develop the necessary knowledge-integration capabilities in 
each pathway. This is consistent with the findings of Gardner et al. (2012) on teams who 
were successful in dynamically integrating members’ resources into higher performance. 
This potential for variation only underscores the need to develop theory around the nature of 
value creation and risk in alternative pathways.  
We also observed how increasing leverage cases were characterized by evidence of 
novel interactions and partnering models in fundamental and applied research. One 
plausible explanation here is that digitalization is now forcing firms to reconsider the overall 
business ecosystem. This is consistent with new modes of strategizing within and across 
firm boundaries (Holmström et al., 2020) where digital platforms and capabilities together 
are giving rise to business value created at the level of the ecosystem and shared by various 
SSRN Working Paper 
 27 
co-contributors (Venkatraman et al., 2014). With familiarity and prior shared experiences 
positively impacting efficiency and quality of outputs (Staats, 2012), many firms have tended 
to collaborate with tried and trusted partners who may have delivered in the past (better the 
devil you know?). In consortia-led digitalization initiatives, firms have been exposed to new 
and previously untested partners but whose contributions may be more novel and potentially 
ground-breaking. This was particularly evident in simultaneous pathways, where ‘unique 
SME-MNC pairings’ aimed to deliver an increasingly diverse scope of applications at ‘non-
standard’ scales. As per appendix 4, our cases also highlighted the interchangeable roles of 
key actors with multiple combination options (e.g., ‘integrator-allocator’, ‘pivot-coordinator’, 
‘navigator-broker’) based around emerging modes of innovation. This is consistent with the 
idea of ‘distributed’ innovation agency involving the dynamic and sometimes unexpected 
collection of actors engaging in the innovation process (Nambisan et al., 2017).  
 
5.2. Appropriability - out with the ‘old’ and in with the ‘new’  
Recalling our definition of appropriability from section 2, our cases provide evidence of 
new routines and standards arising from digital innovations and their subsequent uptake. 
Some of which were initially based on uncertain and very risky hypothesis-driven 
developments. In practical terms, consortia members benefited greatly from adopting 
emerging design rules in their respective firms, which we outlined in section 4.3.2. With 
increasing confidence and trust (uptake of industry-first breakthroughs were seen to greatly 
reduce risk – see cases 10-12) came an increased pool of resources. This enabled 
innovators to influence further outcomes and turn follow-on or complementary projects (often 
chaotic at the outset) into "wins". One plausible explanation here is that with consortia-led 
projects, there are new, specific mitigation processes in play which helped to characterize 
and manage innovation risk profiles in each pathway. This is consistent with the idea of 
consortia as complex adaptive systems (Papadaki and Hirsch, 2013) ‘facing endogenous 
risks as well as exogenous surprises that cannot always be anticipated in advance’ (Lessard 
and Miller, 2001, p.9). We observed how consortia tackled decisions in the face of changing 
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and uncertain environmental conditions and were open to rapid adjustments within 
sequential and simultaneous pathways. This invokes the idea of pathways as 
‘microenvironments’ designed to drive stakeholder alignment and efficient adaptation 
strategies (Papadaki and Hirsch, 2013). 
Traditional engagements involving conventional rules (for compliance) have typically 
resulted in transitory exchanges and once-off interactions between single firms and the UK 
regulator. Indeed, in section 4, we observed how dPPIs have led to multiple incremental 
changes to batch processing routines which have resulted in a myriad of ‘exceptions’ to 
existing rules. One plausible explanation here is moderating firm practices have tended to be 
easy to define and are reactive. This practice promotes numerous, yet minor changes, to 
routines to avoid resistance and mitigate organizational risk. As a result fleeting early 
successes (one-off case studies) involved more bounded innovation outcomes and 
processes, that were observed in traditional firm-firm activities observed pre-2011. This is 
consistent with Quinn (1978) who proposed that effective strategies tend to emerge 
iteratively. Firms probe the future, experiment, and learn from a series of incremental 
commitments.  
Interestingly, the ‘consortia effect’ enabled active engagement and two-way information 
exchanges with the UK regulator in both pathways. In moving away from a traditional 
compliance discussion, collective conversations centered on up-front agreement and follow-
on validation of novel consortium-led digital initiatives e.g., adaptive assembly-to-order 
solutions (case 8) in the sequential pathway. Our simultaneous pathway cases suggest less 
bounded innovation outcomes and processes, often reflected in new success criteria, as 
summarized in Appendix 4. The dynamic here, which might have been expected to be 
particularly challenging, was often focused on leveraging these industry-first breakthroughs 
and in promoting follow-on ‘regulatory innovation’ activities. This is consistent with pre-
competitive consortia enabling a ‘whole-chain’ view, in that they are ‘fact-based rather than 
opinion-based’ (Dooley, 2014, p.1108). As a result of those early successes, consortium 
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members and regulators could choose to go ‘all in’ at times (increasingly more often than 
not) so that novel outcomes are maximized. 
 
5.3. Coherence - transitioning to new modes of operation 
Recalling our definition of coherence from section 2, our cases provide evidence of critical 
communications and cross-sectional activities at higher levels of abstraction being managed 
in both sequential and simultaneous pathways. In practical terms, the ‘Transition’ sub-
network looked to revise traditional practices and ‘transition’ using digitalization capabilities 
developed through consortia engagements. Here, new rules derived by multiple 
engagements involving multiple partners and based around platform-based thinking, and 
other ‘unconventional’ practicalities, were in evidence. This invoked the idea of ‘boundary 
objects’, shared and shareable across different problem solving contexts (Star, 1989 in 
Carlile, 2002). Here, despite substantial differences between our consortia members across 
various disciplines, they nevertheless were very successful in cooperating and transitioning 
to create value and mitigate risks. The mode of innovation was also changing here, 
evidenced by firms abandoning ‘batch’ development in favour of ‘continuous’ approaches. 
One plausible explanation here is that firms have traditionally focused either on the process 
(with limited attention to the innovation outcome) or the innovation outcome (with limited 
attention to the innovation process) (Nambisan et al., 2017). As a result, moderating firm 
practices were often sequential, avoiding those actions that are loaded with risk in 
transitioning to a future (desired) state. However, modifications can be immediate in 
instances where no regulatory changes are needed. With digitalization, dependencies 
between processes and outcomes appear more complex and dynamic, so may constrain or 
shape action, value, and choices along different pathways (Carlile, 2003). Applying this to 
sequential and simultaneous pathways, these boundary objects - objects that work to 
establish a shared context that “sits in the middle” - are somewhat different. They are better 
defined in sequential pathways given its temporal nature, but more blurred in simultaneous 
pathways as interfaces are novel and difficult to scale. This is consistent with Dougherty and 
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Dunne (2012) who proposed that digitalization, in drug discovery contexts, led to a 
reorganization of the innovation focus. The creation of a new and necessary set of activities 
here had implications for innovation outcomes – the effects of which were all unintended.  
 
6. Managerial Implications  
The theoretical propositions described in section 5 have significant managerial implications. 
From a strategic operations management perspective, this research provides insights on 
consortia-based pre-competitive collaborations in the context of innovations involving the 
application of multiple technologies. These technologies traverse product-process 
development and supply chain innovation. We expand on these insights below in terms of 
project portfolio and subsequent consortia development, value appropriation and risk 
mitigation. At the operational level, the central managerial insight that we identify is when to 
adopt the sequential pathway and when the simultaneous pathway is more appropriate, 
primarily in the context of risk mitigation. This presents a major dilemma for innovators, in 
terms of how firms handle this technology configuration challenge i.e., sequential (on the 
surface a more steady approach but loaded with the risk of never arriving at the end-goal 
within a reasonable timeframe) versus ‘all-in’ simultaneous transitions (often seen as loaded 
with risk but with the promise of breakthrough outcomes). We can draw the following insights 
and recommendations from our observations.  
As per Chandrasekaran et al., (2015), project and organizational contexts affect 
performance and are dependent on the type of project. First, at a strategic management 
level, we observe the ‘flywheel effect’ of multiple pre-competitive collaborations that follow-
on from each other as capabilities and trust develops across partners, underpinned by early 
successes and results that then shape longer-term ambitions. The evidence suggests that 
both radical and incremental projects are required to sustain consortia, and this mixed 
portfolio approach is necessary to maintain ‘momentum’. However, firms need to position 
themselves to be able to switch from exploiting existing knowledge to exploring new 
knowledge (March, 1991) and vice-versa, based on business model needs. This finding 
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suggests that both sequential and simultaneous pathways play a critical role in sustaining 
consortia, despite their very different risk profiles. Further, firms and their networks need to 
collectively assess strategies and set up a supporting consortium infrastructure (or a set of 
platforms) to deliver network performance —that is, assessing different pathway choices for 
value creation and risk at a project level, involving both shorter term ROI projects as well as 
platform-level projects that will support the ‘next round’ of pre-competitive collaborations. In 
sequential pathways, ‘use cases’ have typically been the modus operandi but are often 
characterised by ‘tactical gains’ (e.g., new technology adoptions at one process step that is 
implemented for just one product type) as a means of getting internal buy-in within an 
organization, and based on a near term ROI justification. Hence, ‘attractive’ cases often 
determine the pathway choice which can result in short-term incremental activity (but 
possibly never the long term ‘strategic intent’ end-point). In contrast, simultaneous pathways 
require the development of hypotheses and a future vision at a strategic level. Immediate 
ROI is not always apparent as investing in e.g., a platform requires many players and pooled 
resources (intellectual and financial). The consortium effect serves to ‘de-risk the risk 
conversation’, which helps consortium partners sell the hypotheses to internal stakeholders 
in their respective organizations. The consortia model thus leverages individual investments 
with a multiplier effect through the pooling of resources. Further, for novel innovations, the 
regulatory innovation dynamic which might be expected as particularly challenging (and 
prohibitive for single firms), is transformed; the regulator role moves from a compliance-
centric single company discussion, to a ‘co-creation’ platform-building activity.  
The adoption of multiple pathways within consortium models also has significant 
managerial implications. In our study the multiple projects ‘portfolio mix’ provides flexibility, 
each pathway and associated project type with their distinct management approach, itself 
providing a risk-hedging form of mitigation. As projects progress, resources can be re-
directed based on results and re-evaluation of project potential, with project learnings 
informing on-going workstream or platform design. This classification of conventional and 
novel projects is in itself a significant management takeaway; suggesting that perhaps 
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consortia models are essential mechanisms for novel-simultaneous execution projects, but 
perhaps counter intuitively, also for conventional-sequential execution projects to leverage 
knowledge and appropriability for this particular innovation-intensive context. Perhaps also a 
surprising finding is the ‘all-in’ approach is most appropriate from a risk mitigation 
perspective for novel ‘moon-shot’ projects, avoiding the bureaucracy of multiple stage-gate 
ROI centric reviews, a restrictive regulatory regimen and consequent extended timelines. 
The role of institutional players becomes significant for the success of these more radical 
projects, be they the technology providers (universities and SMEs), funding bodies 
(government), first adopters (MNCs), and regulatory bodies, making their participation in 




Consortia members often have very different ideas when it comes to outcomes and risk. 
Some are ambitious with a long-term vision, while others focus on short-term incremental 
gains. This paper outlines three alternative digital innovation pathways that firms navigated 
in the context of pre-competitive consortia. Over eight years, we were privy to the unique 
issues and difficult choices they had to make. For example, what pathway do you take if 
your ultimate goal is a conventional or novel outcome? In practice, this is a major dilemma 
for those structuring and operating within consortia-led innovation projects. Hence, we offer 
an integrated mechanism that might inform when to adopt a sequential pathway, and when 
the simultaneous pathway is more appropriate. 
This paper has elaborated, through empirical case studies, on the orchestration 
processes of network-centric innovations (Nambisan and Sawhney, 2011). We offer mid-
range theoretical insight and propositions for further empirical research, and recognize that 
such studies are required to explore some of the elicit tentative claims we make. However, 
these have opened up promising research opportunities that we are pursuing. First, 
replication and extension in other ecosystems will help to extend our collective 
understanding of sequential and simultaneous digital innovation pathways. If future 
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research, via case-based and survey-based research designs, in other contexts support 
similar arguments we can conclude our results - obtained through abductive reasoning - 
could support inductive studies to confirm generalizable outcomes. Our observations on 
sequential and simultaneous pathways, and allied data-driven decision-making consistent 
with Guha and Kumar (2017), offer a second possibility for future research in terms of 
optimization research. Finally, it will be important to better understand knowledge transfer 
mechanisms, the role of boundary objects and allied operational routine options (Carlile and 
Rebentisch, 2003), i.e., are new types of boundary objects needed to facilitate the directional 
shifts required in alternative pathways?     
Finally, molecules can be divided into two classes – small and large – which significantly 
impacts technology platform choices. Hence, one limitation was a focus on dPPIs and dSCIs 
involving small molecules only. This is an opportunity as competition begins to shift based 
on new business models e.g., impending batch-to-continuous-conversion tipping point 
evidenced by our sample; strategic shifts towards large molecules (e.g., biologics and 
vaccines) and drug-device combinations (Waltz, 2014). Hence, we are considering the 
implications of our propositions as firms seek to make sense of future R&D investments. 
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Appendix 1. UK consortia in this study 
Consortium Website 
Dial-a-Molecule Grand Challenge Network  http://generic.wordpress.soton.ac.uk/dial-a-molecule/ 
 
CIM CMAC (Centre for Innovative Manufacturing in Continuous 
Manufacturing and Crystallization) 
https://www.cmac.ac.uk 
 




ADDoPT (Advanced Digital Design Transforming Pharma 
Development and Manufacture) programme  
https://www.addopt.org 
 
CMAC Hub (Future Continuous Manufacturing and Advanced 
Crystallization Research Hub) 
https://www.cmac.ac.uk; 
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Appendix 2. Sequential case profiles with summary of observed inputs (basic construct analysis) 
 
# Case overview 
Focus 













Limited and embryonic network 
structures; basic product definitions; 
Focus on ‘in-house validation’ initiatives 
Low 
Operating in line with existing routines and 
standards; single-firm optimizations 
 
Low 
Classic trade-offs of speed versus 
accuracy (temporal)  
 
2 
Batch processing with off-line 
analytics 
Process control through fixed 
parameters  
Medium 
Fragmented single-firm networks; 
commercial strategies in place 
 
Low 
Compliance to well-established industry 
standards; fixed parameters 
 
Low 
Conventional end-of-line testing; 
temporal trade-offs as default at scale 
 
3 
Batch processing with on-line 
analytics 
Quality-by-design (QbD) principles 
with novel analytics 
High 
Networks formed around collaborative 
research 
Medium 
Emerging QbD principles for selected 
batch operations  
Medium 
Targeted experimental designs; Risk 
v. return (cross-sectional) trade-offs 
4 
Hybrid processing systems with 
on-line analytics 
Model-based predictive control  
High 
Virtual integrated networks; access to 
consortia-wide capabilities for members  
 
Medium 
Existing (quality control) and emerging 
(quality assurance) standards possible 
 
High 
‘Real-time’ comparisons; ‘ideal’ 
process states predicted and defined 
 
5 
Make-to-stock supply  
High volume centralised models 
Low  
Centralized single-firm arrangements 
Low 
Compliance to well-established industry 
standards; fixed parameters 
Low 
Traditional cost versus quality 
(temporal) trade-offs 
6 Printed electronics Prototypes for ‘track-and-trace’ 
High  
Network formation around process and 
packaging re-design 
High 
Mandated serialization; high potential in 
replacing industry standard 
Low 




Localised on-demand supply 
Low volume dispersed models 
 
High 
Specialists re-designing supply chains for 
flexibility and agility and located closer to 
the points of use 
 
Medium 
Increasing convergence of multiple digital 




Targeted experimental designs; Risk 





Trial designs to accelerate clinical 
phases 
High  
Consortium approach enabling novel 
engagements with regulators 
Medium  
Customised product design 
(‘personalisation’ in terms of country- 
clinic-individual) 
High 
Specialist risk partner focus on risk 
versus high return trade-offs 
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Digital workflow  
E2E Proof-of-Concept demonstrator 
 
Medium 
Select consortia partners 
experimenting with concurrent designs  
Medium 
Compliance to existing standards as a 
benchmark for comparable performance 
Medium 
Prototype framework developed 
for E2E business case transitions 
10 
Plug-and-Play 




Collaborative models gaining traction 
over differentiated approaches 
 
Low 
Qualification using existing standards; 
validation demos for select chemistries  
 
High 
Full-scale transitions via modules 
available at lab and pilot scale 
 
11 
Continuous Filtration  




Network actors demonstrating benefits 
via exemplar case studies  
 
Medium 
Comparable performance (if not better) 
versus manual best practice and 
standards in process development  
 
High 
Defining design space in terms of 
critical material attributes and 
process parameters  
 
12 Next-Generation RFID ‘Smart label’ interventions  
High 
Partnerships teasing out explicit links 
with non-consortium partners 
Low  
Basic compliance and anti-counterfeiting 
focus  
High 




Flexible mobile platforms for low 
volumes  
High 
Network formation around micro-
factory archetypes and concepts 
 
Medium  
Precision medicine driving smaller 
volume production and supply models 
 
High 
Novel network designs; Digital 
twins; elimination of multiple steps 
 
14 
Continuous Extrusion and 3D-Print 
Agile processes for advanced delivery  
 
High  
Consortia-led feasibility studies 
involving some demonstration of 




Looking to existing standards as 
benchmarks; emerging predictive 
models in secondary processing (drug 
product) 
High 
Defining design spaces in terms of 
critical material attributes and 




Next-Generation product concepts 
Developing new types of packaging  
 
High 
Network actors demonstrating benefits 
via exemplar case studies with new 
materials and processing techniques  
Medium 
Potential to replace standard material for 
a wide range of medicines  
High 
Digital standard operating 
procedures; Links to digital leaflets 
and mobile phone apps 
16 
Digitalization Lab 
E2E Proof-of-Concept demonstrator 
 
High  




Data and information to evaluate 
business model-changing shifts 
 
High 
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Appendix 4. Summary of outcomes and the relationship of coherence to leverage and appropriability 
 
















* Principle nodes co-developing ‘data-
driven’ experimentation and brokering 
access to potential end-user groups, as 
pairs of ‘pivots’ and ‘navigators’ related to 
their specialisms; 
* Virtual networks emerging around ‘assets 
and capabilities’ made accessible by 
consortia membership to wider 
communities  
* Principle nodes facilitating moves towards modelling-
based design of drug products and manufacturing 
processes;  
* Experimentation goes beyond traditional DoE by 
leveraging consortiua expertise to support delivery of 
‘targeted’ molecules and ‘robust’ processes;  
* Sequential changes in predictive capabilities now 
enabling ‘real-time’ comparison of batches against 
‘ideal’ process states for selected processes 
* Principle nodes supporting increased 
information flows between digital design activities 
and full-scale manufacturing processes; 
* Experiments around high-volume low-variety 
segments continue to dominate;  
* ‘Quality-by-Design’ (QbD) principles have 









• * Principle nodes co-developing 
‘segmentation-driven’ experimentation  
* New ‘outcome-based’ product delivery 
models coordinated by both clinical and 
commercial central nodes 
* Specialised sub-networks commissioned 
to design clinical trials and protocols with 
built-in flexibility and agility 
* Principle nodes facilitating enhancement of traditional 
‘make-to-stock’ supply models using ‘adaptive’ 
approaches enabled through digital information  
* Sequential changes in process and packaging 
redesign supporting potential for more Quality 
Assurance (QA) dominant product releases in certain 
cases   
* Data systems reconfigured for improved traceability 
and compliance monitoring, requiring new regulatory 
constructs 
* Principle nodes supporting moves towards more 
‘coopetition’ at platform level with potential for 
rapid two-way transfer of design (clinical) and 
manufacturing (commercial) data  
* While hitherto sequential in nature, 
experimentation around increasing SKUs sees 
partners leveraging consortium links  
* New design rules emerging linked to archetypes 









* To deliver a diverse scope of applications, 
central nodes coordinating ‘unique pairings’ 
for ‘platform-based strategies’  
* Hybrid role of central nodes based around 
evolving modes of dPPI and/or dSCI; often 
interchangeable with multiple combinations 
in play 
* Central nodes increasingly using 
language around ‘new measures’, ‘levels of 
‘modularisation’, ‘scale juxtapositioning,’ 
capabilities for ‘convergence’ and 
‘precision’ 
* To meet future techno-social sector requirements, 
PPI and SCI dimensions become fundamentally 
different in simultaneous pathways  
* Consortium effect enabling shifts from ‘passive’ 
interactions (single-firm) towards unique conversations 
and transactions beyond the ‘norm’ (platform-based) 
* While coopetition on quality, dependability, service 
and cost required as ‘qualifiers’, competition now 
shifting to other measures, depending on new business 
models 
* Simultaneous pathways imply a ‘de facto’ 
platform approach with the emergence of new 
design rules (supported by the regulator) 
* Increasing focus on ‘data organization’, the E2E 
integration of ‘modular’ and continuous process 
innovations that operate at much lower and 
unconventional scales  
* Radically new supply network configurations 
with potential sea-change requirements in supply 
collaboration, site location, capacity, inventory, 
and customer engagement being assessed using 
digital network design tools 
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Consortia contact Data collection (initial 2 phases) 
2011-2016 (sequential cases); 
2014-2016 (sequential and 
simultaneous cases) 
 
Data analysis Data collection (final 
phase) and analysis  
2016-2018 (sequential and 
simultaneous cases) 
Final analysis and 







academic and sector 
specialists not 
aligned to consortia 
under study 
Senior industrialists, managers, 
engineers, and scientists;  
Academic-Industry workshop-type 
engagements focused on specific 
themes and consortia outcomes;  
lab-scale, pilot-scale and production 
plant visits 
Workshop reports; field 
notes; Academic 
publications;  
White papers developed 
by consortia members 
 
Senior industrialists, 





and scientists; Coded 
interviews and 
workshop-type 
engagements. All other 
data sources from initial 















Industrial system mapping 
techniques: ‘micro-maps’ charting 
evolutions and patterns pre-2011 and 
from 2011-2016; 
Interview protocols; Broad open-
ended questions common to and 
across cases; follow up based on 
specific and emerging themes during 
workshops;  
Further evidence to support 
(academic papers and other 
secondary data relating to consortia 







Industrial system mapping 
charting evolutions 2016-
2018; Interview protocols are 
case and respondent 
specific; Created dynamically 
in this 2-year final phase as 
the data collection process 
unfolds; To close out phase, 
key stakeholders are asked 
to comment on emerging 
trends and generalised 
patterns from initial 2 phases 
of data analysis 
Specific questions or 
information asked to 
some respondents in 
order to verify alternative 
explanations and 


















Case summary ‘dossiers’ 
capturing value and risk 
propositions; network 
analysis (NA) and coding 
procedures followed to 
operationalise the main 
constructs, identify 
patterns and make 
interpretations  
NA to highlight patterns 
relating to experimentation 
and specific sub-networks;  
Coding procedures as 
before; Construct-oriented 
comparisons are made to 
highlight patterns 
 
NA to draw inferences 
for entire networks and 
innovation pathways 
using sub-networks;  
Construct-oriented 
comparisons are made 
to highlight patterns and 
codify key trends 
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On-line Appendix A2 . Sampling Grid 
 
Sequential Network Experimentation (cases 1-8)  
dPPI or dSCI focus 
Simultaneous Network Experimentation (cases 9-16)  
dPPI and dSCI focus 
(1) Batch development (base case) 
dPPI: Improving lab-scale ‘design of experiment’ (DoE) approaches 
Context: Low volume and low variety; API unit operations 
(9) Digital workflow  
dPPI: Demonstrating feasibility for batch and continuous processes  
dSCI: Optimising performance in line with dPPI 
Context: E2E Proof-of-Concepts; High volume and low variety 
(2) Batch processing with off-line analytics 
dPPI: Reducing conventional batch-to-batch variation 
Context: High volume and low variety; API unit operations 
(10) Plug-and-Play 
DPPI: Implementing continuous-dominant processes with analytics  
DSCI: Optimising performance in line with dPPI 
Context: API; Mobile platforms; High volume and low variety dominant 
(3) Batch processing with on-line analytics 
dPPI: Reducing conventional batch-to-batch variation; implementing 
process analytics 
Context: High volume and low variety dominant; API unit operations 
(11) Continuous Filtration  
dPPI: Implementing continuous-dominant processes with analytics  
dSCI: Optimising performance in line with dPPI 
Context: Drug product; Agile processes; Low volume and high variety 
(4) Hybrid processing systems with on-line analytics 
dPPI: Reducing conventional batch-to-batch variation; implementing 
process analytics and continuous mode for selected unit operations  
Context: High volume and low variety dominant; API unit operations 
(12) Next-Generation RFID 
dPPI: E2E integration with continuous-dominant processes (API and Drug Product) 
dSCI: Optimising performance in line with dPPI 
Context: Digital Supply; Intelligent packs; High volume and low variety 
(5) Make-to-stock supply (base case) 
dSCI: Reducing inventory levels  
Context: High volume and low variety; commercial supply 
(13) Micro-factories 
dPPI: Implementing continuous-dominant processes with analytics  
SCI: Optimising performance in line with dPPI 
Context: API; Mobile platforms; Low volume and high variety 
(6) Printed electronics 
dSCI: Optimising inventory levels  
Context: High volume and low variety; commercial supply 
(14) Continuous Extrusion and 3D-Print  
dPPI: Implementing continuous-dominant processes with analytics  
dSCI: Optimising performance in line with dPPI 
Context: Drug product; Agile processes; Low volume and high variety 
(7) Localised on-demand supply 
dSCI: Optimising inventory levels  
Context: High volume and low variety dominant; clinical supply 
(15) Next-Gen product concepts 
dPPI: E2E integration with continuous-dominant processes (API and Drug Product) 
dSCI: Optimising performance in line with dPPI 
Context: Digital supply; Intelligent packs; Low volume and high variety 
(8) Adaptive assembly-to-order solutions 
dSCI: Optimising inventory levels  
       Context: High volume and low variety dominant; clinical supply 
(16) Digitalisation Lab 
dPPI: Demonstrating feasibility of continuous processes  
dSCI: Optimising performance in line with dPPI  
Context: E2E Proof-of-Concept; Low/high volume and high/low variety 
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Online Appendix A3. Network Analysis 
 









Entity ID Eigenvector  Sub-network
Academic Institution 1 B09 1.00 Integration; Design Rules
Academic Institution 2 B12 1.00 Integration; Design Rules
MNC 1 B01 0.97 Integration; Design Rules
MNC 2 B02 0.97 Integration; Design Rules
Academic Institution 3 B15 0.97 Integration; Design Rules
MNC 3 B06 0.95 Integration; Design Rules
Academic Institution 4 B10 0.80 Application
Academic Institution 5 B11 0.80 Application
Academic Institution 6 B13 0.80 Application
Academic Institution 7 B14 0.80 Application
MNC 4 B03 0.78 Application
MNC 5 B04 0.78 Application
MNC 6 B07 0.78 Application
MNC 7 B08 0.78 Application
MNC 8 B05 0.56 Application
SME 1 B16 0.56 Transition; Design Rules
SME 2 B17 0.56 Transition; Design Rules
SME 3 B18 0.56 Transition; Design Rules
AMSCI Funding Body B20 0.56 Application
MMIP B22 0.46 Application
ReMediES consortium B23 0.43 Application
EPSRC Research Council B19 0.43 Application
Knowledge Transfer Network B21 0.43 Application
















Entity ID Eigenvector Sub-network
Academic Institution 1 C05 1.00 Integration; Design Rules
MNC 1 C01 0.89 Integration; Design Rules
MNC 2 C02 0.70 Integration; Design Rules
UK Regulator C09 0.68 Application
SME 4 C06 0.67 Application
UK Centre for Process Innovation C07 0.62 Transition; Design Rules
SME 5 C08 0.49 Transition; Design Rules
AMSCI Funding Body C10 0.36 Application
CMAC Consortium C11 0.32 Application
Logistics Provider 1 C04 0.32 Application
Pharmacy Chain 1 C03 0.19 Application
External specialist supplier C12 0.17 Application















Entity ID Eigenvector  1 Sub-network
MNC 1 D01 1.00 Integration; Design Rules
Academic Institution 1 D03 1.00 Integration; Design Rules
MNC 2 D02 0.94 Integration; Design Rules
Academic Institution 2 D04 0.90 Integration; Design Rules
IIM (MNC 1) D24 0.85 Integration; Design Rules
CMAC Consortium D23 0.82 Integration; Design Rules
SME 1 D07 0.64 Transition; Design Rules
SME 6 D08 0.62 Transition; Design Rules
SME 7 D11 0.62 Transition; Design Rules
SME 8 D13 0.62 Transition; Design Rules
SME 9 D15 0.62 Transition; Design Rules
SME 10 D17 0.62 Transition; Design Rules
SME 11 D09 0.62 Transition; Design Rules
SME 12 D10 0.62 Transition; Design Rules
SME 2 D12 0.62 Transition; Design Rules
SME 3 D14 0.62 Transition; Design Rules
SME 13 D19 0.57 Transition; Design Rules
UK Skills Agency D22 0.54 Transition; Design Rules
UK Regulator D20 0.42 Application
SME 4 D05 0.33 Application
SME 14 D18 0.33 Application
SME 15 D06 0.30 Application
UK Centre for Process Innovation D16 0.30 Application
AMSCI Funding Body D21 0.26 Application
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Comments on the Outcomes Observed in Applications sub-networks 
Value  
Creation Risk 




Incremental improvements to multiple arrangements and repetitions of unit operations in batch-mode; continued spends of c. 20% of 
revenues on rework, inspection, and testing 
3 Conventional Low Incremental improvements to existing processes; emerging QbD principles but quality control regimes still the norm 
4 Novel High Targeting capabilities for better prediction of experimental outcomes; open access across consortia with adoption of Electronic Laboratory Notebooks for the rapid exchange of reaction and processing data 
5 
Conventional 
Low Base case; traditional batch processing models driving high levels of inventory; for the top 25 pharma companies combined, stock value is estimated to be in the order of $100-150 billion 
6 Conventional Low Compliance over performance remit; novel value potential (and currently far from realisation) sees opportunities for flexible ‘best before’ labels that might disrupt multiple elements of hitherto conventional delivery models 
7 Conventional Low Incremental changes to paper batch record system and manually-operated production lines; Potential for control systems and data management to enable more frequent and lower volume runs than is currently achievable  
8 Novel High Better ‘targeted’ designs through data analytics;  Potential to collapse standard transaction and processing times and eliminate costly write-offs of unused clinical stock, typically in excess of £50 million per MNC per year  
9 Conventional  Low Incremental changes to-date given the bench-marking performance remit; initial concurrent thinking around new supply network design principles linked to PPIs 
10 Novel Medium Recently validated ‘targeted’ API-specific applications in mobile continuous crystallization processing with first-time translation beyond proof of concept experimentation and pilots to front-line manufacturing use.  
11 Novel Medium Step change to continuous-mode enabled by predictive capabilities; Reduced risk in scale-up of manufacturing processes and combinations of different unit operations; Opportunities to accelerate the design and modelling of new and more challenging APIs 
12 Novel Medium Initial breakthroughs with the development of concepts to replace industry standard rigid ‘temptales’ with a flexible label based on Near-Field-Communications (i.e. utilising an Android mobile phone to read the data) 
13 Novel High 
Focus on ‘niche’ product-process archetypes with lower inventories, shorter times to market, with scale-matching; platform-based 
design principles emerging based on new paradigms of ‘process intensification’, ‘miniaturization’ and ‘combinations’ in continuous 
modes; Digital twins linked to integrated continuous ‘direct-to-dose’ schemes 
14 Novel High 
Conventional PPIs in dosage form design and processing cannot meet future needs of personalised medicine. Extrusion technology 
demos now producing oral solid dosage forms in one continuous process; With additional 3D-printing functionality, might provide viable 
options for extremely flexible dosing, rapid and optimised product design, low material usage and on-demand supply.  
15 Novel High New process trials with potential to deliver savings of £2 million on materials and distribution per annum per MNC; ‘just-in-time’ technologies demonstrating potential for reducing lead-times from 4-6 months to <1 week 
16 Novel High 
High-level strategic goal involves using a range of diverse digital technologies to ‘connect’ previously disparate upstream and 
downstream operations. Key to this is integration of data generated along the product lifecycle in a variety of digital contexts 
 
